Cogent Insider Sells $2.5 Million in Stock Amid Staggering 300% Price Surge

3 hours ago 1

Jonathan Ponciano, The Motley Fool

Sun, January 11, 2026 astatine 2:15 PM CST 5 min read

According to a Form 4, 1 Cogent Biosciences insider sold 65,000 shares of the biotech connected Dec. 26 for a full worth of $2.52 million.
This merchantability represented 37.27% of Evan Kearns's nonstop holdings, arsenic reported, reducing nonstop ownership to 109,398 shares.
No indirect holdings oregon derivative transactions were involved; each shares were disposed of from nonstop ownership.
These 10 stocks could mint the adjacent question of millionaires ›

Evan Kearns, the main ineligible serviceman astatine Cogent Biosciences (NASDAQ:COGT), reported an open-market merchantability of 65,000 shares for a transaction worth of $2.52 million, according to a Dec. 30 SEC Form 4 filing.

Metric

Value

Shares sold (direct)	65,000
Transaction value	$2.5 million
Post-transaction shares (direct)	109,398
Post-transaction worth (direct ownership)	$4.25 million

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($38.70); post-transaction worth based connected Dec. 26 marketplace adjacent terms utilized successful SEC calculations.

How important was the simplification successful Evan Kearns's holdings arsenic a effect of this transaction?
The merchantability reduced Kearns's nonstop ownership by 37.27%, leaving him with 109,398 shares, notably shrinking his nonstop vulnerability to Cogent Biosciences equity.
Did the transaction impact immoderate derivative oregon indirect interests?
No; the filing confirms each shares sold were held directly, with nary engagement of equity awards, trusts, oregon different indirect entities.
How does the transaction size comparison to Kearns's trading history?
This is the sole open-market merchantability by Kearns successful the disposable record, truthful nary recurring commercialized size inclination is evident for open-market dispositions.
What is the existent marketplace discourse for Cogent Biosciences shares?
As of Dec. 26, the past reported terms applicable to the transaction was $38.70, reflecting a one-year full instrumentality of 345.38%, portion Kearns's post-sale holdings held an approximate marketplace worth of $4.25 million.

Metric

Value

Price (as of marketplace adjacent 12/26/25)	$38.70
Market capitalization	$4.95 billion
Net income (TTM)	($294.37 million)
1-year terms change	345.38%

Cogent's pb merchandise campaigner is CGT9486, a selective tyrosine kinase inhibitor targeting KIT D816V and different KIT exon 17 mutations, with a absorption connected systemic mastocytosis and precocious gastrointestinal stromal tumors.
The biotech operates a precision medicine model, processing targeted therapies for genetically defined diseases, with gross imaginable tied to palmy cause improvement and commercialization, including licensing agreements specified arsenic with Plexxikon Inc. for bezuclastinib.
Its superior customers are healthcare providers, oncologists, and institutions treating patients with uncommon familial diseases and cancers driven by circumstantial mutations.